GlassScriptPhysician profile
Dongmei Wang
NPI 1447422431
$6,275.11
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,365 · 2020: $3,793 · 2022: $20.70 · 2024: $96.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $96.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $96.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,520.53 | 2019-2020 | |
| Janssen Biotech, INC. | $382.81 | 2019-2020 | |
| Genentech USA, INC. | $246.80 | 2019-2022 | |
| Pfizer INC. | $201.74 | 2019-2020 | |
| Amgen INC. | $186.20 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $137.45 | 2019 | |
| Penumbra, INC. | $129.31 | 2019 | |
| Novartis Pharmaceuticals Corporation | $121.80 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $117.28 | 2019-2020 | |
| Heron Therapeutics, INC. | $98.27 | 2019-2020 | |
| Inspire Medical Systems, INC. | $96.00 | 2024 | Inspire |
| Gilead Sciences, INC. | $90.87 | 2019 | |
| Sunovion Pharmaceuticals INC. | $90.11 | 2019 | |
| Incyte Corporation | $85.82 | 2019 | |
| Vertos Medical, INC. | $77.74 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $65.74 | 2019 | |
| Novo Nordisk INC | $62.35 | 2019 | |
| Emd Serono, INC. | $46.36 | 2019 | |
| Foundation Medicine, INC. | $45.51 | 2019-2020 | |
| Lilly USA, LLC | $43.00 | 2019-2020 | |
| Astellas Pharma US INC | $42.43 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.88 | 2019 | |
| Rigel Pharmaceuticals, INC. | $37.57 | 2019 | |
| Celgene Corporation | $35.42 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.71 | 2019 | |
| Genzyme Corporation | $26.09 | 2019 | |
| Taiho Oncology, INC. | $25.35 | 2019 | |
| Jazz Pharmaceuticals INC. | $20.00 | 2019 | |
| Seagen INC. | $19.00 | 2019 | |
| Abbvie INC. | $18.49 | 2019 | |
| Daiichi Sankyo INC. | $14.40 | 2019 | |
| Eisai INC. | $14.38 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $14.11 | 2019 | |
| Bio Products Laboratory USA, INC. | $12.04 | 2019 | |
| Exelixis INC. | $11.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dongmei Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.